Brief: UCB's BIMZELX Demonstrates Sustained Disease Control In Hidradenitis Suppurativa

UCB SA

12/02/2025 07:10

Feb 12 (Reuters) -  UCB.BR :
    * ANNOUNCED LONG-TERM DATA FROM THE BE HEARD TRIALS FOR
BIMZELX(BIMEKIZUMAB)IN MODERATE TO SEVERE HIDRADENITIS
SUPPURATIVA (HS)
    * AFTER TWO YEARS OF BIMZELX(BIMEKIZUMAB)TREATMENT, 53.1% OF
PATIENTS HAD MILD DISEASE COMPARED TO 0.0% AT BASELINE
    * AT TWO YEARS, 83.4% OF PATIENTS WITH HIDRADENITIS
SUPPURATIVA
(HS) REMAINED FLARE-FREE

        
 Source text:  ID:nNDL16DmD9 
 Further company coverage:  UCB.BR  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))